Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Muscarinic receptor ligand selected for further study

July 12, 1996

First demonstration of cellular mechanism of human oral tolerance

July 12, 1996

First approval of SmithKline Beecham's ReQuip in U.K.

July 12, 1996

Lundbeck's Serdolect reaches first market

July 12, 1996

Pharmacia & Upjohn's dopamine D4 receptor ligands

July 12, 1996

Potent, selective mGluR2 agonist from Lilly

July 12, 1996

Potential CNS disorders treatment from Janssen

July 12, 1996

Melatonin effective for jet lag/shift lag

July 12, 1996

Lilly describes heterocyclic tachykinin antagonists

July 12, 1996

Faulding's Kadian approved by FDA

July 12, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...